Skip to main content

Table 1 Baseline characteristics of 222 myeloma patients

From: Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma

 

No. of patients (%)

P value*

Non-BSI

(n = 196)

BSI

(n = 26)

Gender

     

 Male

141

(72)

17

(65)

0.492

 Female

55

(28)

9

(35)

 

Age ≥ 65 y/o

127

(65)

19

(73)

0.402

Myeloma subgroup

 IgG

95

(48)

13

(50)

0.741

 IgA

63

(32)

9

(35)

 

 Light chain disease

29

(15)

4

(15)

 

 Other typesa

9

(5)

0

(0)

 

Immunoglobulin status

 Severe Ig deficiencyb

177

(90)

23

(88)

0.767

 Others

19

(10)

3

(12)

 

ALC count ≥ 1000 (/ul)

138

(70)

17

(65)

0.612

ISS Stage

 I

37

(19)

1

(4)

 

 II

64

(33)

5

(19)

 

 III

95

(48)

20

(77)

0.019

ECOG PS >2

59

(30)

17

(65)

<.001

Hb < 10 (g/dL)

108

(55)

21

(81)

0.015

Ca > 12.0 (mg/dL)

14

(7)

5

(19) (58)

0.038

Cr ≥ 2.0 (mg/dL)

55

(28)

15

 

0.002

Induction chemotherapy

 VAD-based

57

(29)

13

(50)

 

 MP-based

83

(42)

7

(27)

0.064

 Othersc

30

(15)

1

(4)

 

 No

26

(13)

5

(19)

 
  1. Abbreviations: BSI Blood stream infection, IgG Immunoglobulin G, IgA Immunoglobulin A, Ig Immunoglobulin, ALC Absolute lymphocyte count, ISS International Staging System, ECOG PS Eastern Cooperative Oncology Group Performance Status, Hb Hemoglobin, Ca Calcium, Cr Creatinine, VAD Vincristine/doxorubicin/dexamethasone, MP Melphalan/prednisolone
  2. aOther types include solitary plasmacytomas and plasma cell leukemia
  3. bSevere Ig deficiency is defined as both of the non-myeloma immunoglobulin levels less than one-fourth of lower normal limit
  4. cIncluding newer regimens such as thalidomide/dexamethasone (TD), bortezomib/cyclophosphamide/dexamethasone (BCD), bortezomib/dexamethasone (BD), cyclophosphamide/thalidomide/dexamethasone (CTD), and bortezomib/cyclophosphamide/dexamethasone (BTD)
  5. *Statistics analysis is used Chi-square or Fisher exact test